Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Mitsuo Higashimori"'
Autor:
Reiko Watanabe, Toshio Kawata, Shinya Ueda, Takumi Shinbo, Mitsuo Higashimori, Yayoi Natsume-Kitatani, Kenji Mizuguchi
Publikováno v:
Molecular pharmaceutics. 20(1)
The contribution ratio of metabolic enzymes such as cytochrome P450 to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d98792387eff1224f7d225e1cf702496
https://pubmed.ncbi.nlm.nih.gov/36538346
https://pubmed.ncbi.nlm.nih.gov/36538346
Publikováno v:
Folia Pharmacologica Japonica. 158:89-100
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::72fe66e980dfa81fcc13563ce52c0074
https://doi.org/10.1254/fpj.22107
https://doi.org/10.1254/fpj.22107
Autor:
Souichi Suenobu, Keita Terashima, Masaharu Akiyama, Tomoyo Oguri, Asako Watanabe, Masatoshi Sugeno, Mitsuo Higashimori, Karen So, Yoshihiro Nishida
Publikováno v:
Neuro-Oncology Advances.
Background Plexiform neurofibromas (PN) are a manifestation of neurofibromatosis type 1 (NF1) that may cause morbidity and impact health-related quality of life (HRQoL). Selumetinib (ARRY-142886, AZD6244) is an orally available, selective, mitogen-ac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4b080c66e4700158d268815a96b402f2
https://doi.org/10.1093/noajnl/vdad054
https://doi.org/10.1093/noajnl/vdad054
Publikováno v:
Nihon yakurigaku zasshi. Folia pharmacologica Japonica. 158(1)
Andexanet alfa is a modified recombinant human factor Xa (FXa) that was designed to serve as a binding target for FXa inhibitors as decoy protein. It sequesters FXa inhibitors from binding to endogenous FXa, thereby reversing anticoagulant effect of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0ba47ea91b6542f4fabb4981452e6d79
https://pubmed.ncbi.nlm.nih.gov/36596498
https://pubmed.ncbi.nlm.nih.gov/36596498
Publikováno v:
Int. Journal of Clinical Pharmacology and Therapeutics. 58:29-36
Purpose The objective of this study was to improve the predictive performance of cytochrome P450 (CYP) 2C19 substrates in Japanese subjects using physiologically based pharmacokinetic (PBPK) modeling. Materials and methods Esomeprazole, a CYP2C19 sub
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16ab0e6479c81217e895de5e23950e93
https://doi.org/10.5414/cp203488
https://doi.org/10.5414/cp203488
Autor:
PD Task Force, S. Mita, Tomohisa Saito, Saori Yaguchi, Masaru Hirano, Hisao Ochiai, Katsutoshi Hara, Toshiaki Tanaka, Junichi Yamamoto, Masanori Yamada, Mitsuo Higashimori, Toshiko Koue
Publikováno v:
Clinical pharmacology in drug development. 10(12)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94f5ff0a38351578dd055055dfc451fc
https://pubmed.ncbi.nlm.nih.gov/34837487
https://pubmed.ncbi.nlm.nih.gov/34837487
Autor:
Mario Nagase, Mitsuo Higashimori, Shinya Ueda, Katsuomi Ichikawa, Nidal Al-Huniti, James Dunyak
Publikováno v:
Pharmaceutical Statistics. 19:22-30
As described in the ICH E5 guidelines, a bridging study is an additional study executed in a new geographical region or subpopulation to link or "build a bridge" from global clinical trial outcomes to the new region. The regulatory and scientific goa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::921f43957b39d1057a4a8ad99ec7abe9
https://doi.org/10.1002/pst.1967
https://doi.org/10.1002/pst.1967
Autor:
Martin Johnson, Haiyi Jiang, Mitsuo Higashimori, Fredrik Nyberg, Weifeng Tang, Helen Tomkinson, Yohji Itoh, Yusuke Tanigawara, Toshio Kawata
Publikováno v:
Cancer Chemotherapy and Pharmacology. 83:849-858
A prospective, multicenter, large-scale cohort with a nested case–control study (NCT00252759) was conducted to identify and quantify risk factors for interstitial lung disease (ILD) in Japanese patients with non-small-cell lung cancer who received
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53a4f31e1c817ebdaad046736110cb66
https://doi.org/10.1007/s00280-019-03788-4
https://doi.org/10.1007/s00280-019-03788-4
Publikováno v:
Journal of pharmaceutical sciences. 110(1)
Glycopyrronium bromide, a synthetic anticholinergic agent used to treat patients with chronic obstructive pulmonary disease (COPD), is eliminated from the body by renal excretion and therefore systemic exposure is expected to be increased in patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9052dc9a3b16a9714fc23071aec2144b
https://pubmed.ncbi.nlm.nih.gov/32240691
https://pubmed.ncbi.nlm.nih.gov/32240691
Autor:
Nidal Al-Huniti, Jennifer Sheng, Katsuomi Ichikawa, Li Zhou, Kai Shen, Diansong Zhou, Mitsuo Higashimori, Zhenxian Zhang, Masato Horiuchi, Hongmei Xu
Publikováno v:
Clinical pharmacology and therapeutics. 105(6)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ba1def5b1f881774fe1da9a25003db9
https://pubmed.ncbi.nlm.nih.gov/30802932
https://pubmed.ncbi.nlm.nih.gov/30802932